Simultaneous vaccination for influenza and COVID-19 will potentially be a relief to the health system and to patients during a pandemic..
In the context of controlling the safety and efficacy of co-administration of an influenza vaccine and a COVID-19 vaccine (ChAdOx1 or BNT162b2) a polycentric was performed, randomized, phase 4 study in adults to take either the flu vaccine or placebo with the second dose of their COVID-19 vaccine and three weeks later to get the flu vaccine if they took placebo or vice versa, and its results were published in the international journal "The Lancet".
The Doctors of her Therapeutic Clinic Medical School of the National and Kapodistrian University of Athens Theodora Psaltopoulou, Panos Malandrakis, Giannis Danasis and Thanos Dimopoulos (Rector of EKPA) summarize the relevant publication:
- The primary endpoint of the study was some systematic response to 7 days after vaccination and the antibody response of the participants was also evaluated.
- In total they were included 679 individuals, of which 340 received both vaccines at the same time and 339 successively with 21 difference days.
- In different subgroups that received three different influenza vaccines together with the company vaccine Pfizer or her AstraZeneca, the non-inferiority of concomitant administration with respect to administration with 21 vacuum days confirmed in 4 from the 6 different combinations of vaccines, in the other two the non-inferiority did not meet the statistical criteria established in the design of the study.
- Immune responses were not affected by concomitant infusion and most reactions were mild to moderate.
- A serious side effect has been reported, hospitalization due to headache.
in conclusion, Co-administration has been shown to be safe and effective in this group of patients and could potentially ease the health system next winter.